BA
IBRX icon

BlackRock Advisors’s ImmunityBio IBRX Stock Holding History

BlackRock Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$55K Sell
9,607
-601
-6% -$4.01K ﹤0.01% 3232
2016
Q3 		$79K Buy
10,208
+5,318
+109% +$39.7K ﹤0.01% 3115
2016
Q2 		$30K Buy
4,890
+2,547
+109% +$19.8K ﹤0.01% 3344
2016
Q1 		$19K Hold
2,343
– – ﹤0.01% 3440
2015
Q4 		$41K Sell
2,343
-170
-7% -$2.52K ﹤0.01% 3272
2015
Q3 		$29K Buy
+2,513
New +$54.8K ﹤0.01% 3422

Other funds holding IBRX

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's IBRX Position: Q4 2016 in Review

BlackRock Advisors reduced its ImmunityBio (IBRX) stake by 5.9% in Q4 2016, selling an estimated $4.01K and leaving 9,607 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #3232.

BlackRock Advisors first reported a position in IBRX in Q3 2015 and has held it in 6 quarters since. The position peaked at $79K in Q3 2016. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

  • BlackRock Advisors held 9,607 shares of ImmunityBio worth $55K as of Q4 2016.
  • BlackRock Advisors sold 601 ImmunityBio shares in Q4 2016, an estimated $4.01K.
  • ImmunityBio made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3232 holding.
  • BlackRock Advisors first reported a position in ImmunityBio in Q3 2015 and has held it in 6 quarters since.
  • BlackRock Advisors's ImmunityBio position peaked at $79K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.